Repros Therapeutics — Investor Presentation (May 2017)
16 slides from Repros Therapeutics's investor presentation, May 17, 2017
Slide 1: Repros Therapeutics Corporate Presentation May 2017
REPROS THERAPEUTICS CORPORATE PRESENTATION MAY 2017 Dedicated to Treating Male and Female Reproductive Disorders
Slide 2: Safe Harbor
SAFE HARBOR Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties
Slide 3: Company Overview
COMPANY OVERVIEW • Originally founded as Zonagen – an animal health company using technology from Baylor University • IPO 1993 • Key recent developments • Patrick Fourteau named as Chairman of the Board • Larry Dillaha, M.D. named President and CEO • Important patent issuance with coverage until 202
Slide 4: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM • Larry Dillaha , M.D. – President and CEO (Feb 2017) • Sanofi, Sciele / Shionogi, Insys Therapeutics • History of clinical and regulatory success • Kathi Anderson, CPA – CFO • Joined Repros in 2002 • More than 15 years in biotech, life sciences • Joe Wernicke, M.D., Ph.D
Slide 5: Proellex (Telapristone Acetate) for Uterine Fibroids and Endometriosis
PROELLEX ® ( TELAPRISTONE ACETATE) FOR THE TREATMENT OF UTERINE FIBROIDS AND ENDOMETRIOSIS • Licensed from NIH, 1999 • Selective Progesterone Receptor Modulator (SPRM) • No selectivity for glucocorticoid receptor • Need for chronic intermittent dosing • Lead Indications: • Treatment of Uterine Fibro
Slide 6: Selective Progesterone Receptor Modulator (SPRM)
SELECTIVE PROGESTERONE RECEPTOR MODULATOR (SPRM) • Evolved from Progesterone Antagonists • Mifepristone • Limited use because of high affinity for glucocorticoid receptor over progesterone receptor • Recognizing need for more selective progesterone receptor activity, SPRMs developed • Mixed agonist
Slide 7: Uterine Fibroids
UTERINE FIBROIDS • Benign smooth muscle tumors of uterus ( leiomyomas ) • Most common tumor of female reproductive tract • 20 - 77% of women aged 35 - 55 • Quality of Life often impacted • Heavy menstrual bleeding • Discomfort and pain • Current Therapy • Medications • NSAIDS, OCPs, GnRH agonists, P
Slide 8: Endometriosis
ENDOMETRIOSIS • Endometrial tissue growing outside the uterus • Infertility – Pain, including pelvic pain • Dyspareunia • Dysmenorrhea • 11% of women aged 15 - 44 • 25 - 40% of all cases of infertility • 71 - 87% of women with chronic pelvic pain • 53% teenagers with dysmenorrhea • Impact on QoL • C
Slide 9: How Antiprogestins Like Proellex Work
HOW ANTIPROGESTINS LIKE PROELLEX® WORK GnRH agonists and antagonists. These agents: • Block hypothalamus / pituitary axis • Shut down hormonal secretions • Add - back hormonal therapy Proellex ® Hypothalamus Pituitary Endometrial & Uterine Tissue Antiprogestins • Selectively block progesterone activ
Slide 10: Proellex Effectiveness in Patients
PROELLEX ® EFFECTIVENESS IN PATIENTS 10 AN EFFECTIVE DOSE OF PROELLEX ® STOPS MENSTRUATION IN MAJORITY OF WOMEN Induction of amenorrhea relieves key symptoms of uterine fibroids and endometriosis 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhe
Slide 11: Broad Patent Position on Proellex
BROAD PATENT POSITION ON PROELLEX ® • Off Drug Interval • Recent issuance of patent ‘074 – expires 2027 • Relates to the use of Selective Progesterone Receptor Modulators (SPRM), in particular Telapristone Acetate (Proellex ® ) or Ulipristal Acetate, with an Off Drug Interval (ODI) for the treatment
Slide 12: Regulatory / Development History
REGULATORY / DEVELOPMENT HISTORY 12 Full Clinical Hold 2009 Partial Clinical Hold Phase II studies FDA Meeting Await FDA Feedback • Study doses 12mg and lower • Submit protocols • Increased liver monitoring • Doses of 50mg and 25mg • 2 cases of Hy’s Law at 50mg only • 6mg and 12 mg • Uterine Fibroid
Slide 13: Expected Regulatory Path Forward for Proellex
EXPECTED REGULATORY PATH FORWARD FOR PROELLEX ® • Repros has empaneled group of liver experts to review data and provide opinion • Reached agreement with division to accept additional information from Repros, including opinion from company’s liver experts, for submission to FDA internal liver panel
Slide 14: Significant Market Opportunity and Investment in This Therapeutic Area
SIGNIFICANT MARKET OPPORTUNITY AND INVESTMENT IN THIS THERAPEUTIC AREA • Ulipristal Acetate • Gedeon Richter product Partnered with Allergan for US market • On market in EU • Esmya 5 mg for Tx of UF • Recently completed phase III • Venus II trial • Publicly stated intent to file NDA in 2H17 • $520mi
Slide 15: Enclomiphene for the Treatment of Secondary Hypogonadism
ENCLOMIPHENE FOR THE TREATMENT OF SECONDARY HYPOGONADISM • NDA submitted Jan 2015 • Complete response letter received Nov 2015 • EMA filing under review present in EU market • Opinion date is anticipated in 1Q18 • Actively seeking partnering opportunities ex US 15
Slide 16: Repros: Next Steps and Milestones
REPROS: NEXT STEPS AND MILESTONES • Continue discussions with FDA and obtain feedback to determine future clinical trial program for Proellex ® for Uterine Fibroids and Endometriosis • Submit Proellex ® trial design to FDA • EMA filing under review for Enclomiphene for secondary hypogonadism • New m
Repros Therapeutics — Investor Presentation (May 2017) on 6ix